Oppenheimer resumes Centessa Pharmaceuticals stock coverage with Outperform rating

Oppenheimer has resumed coverage of Centessa Pharmaceuticals (CNTA) with an Outperform rating and a $40 price target, citing strong conviction in its lead asset ORX750, a potential best-in-class orexin-2 receptor agonist. The firm anticipates crucial Phase 2a data for ORX750 in idiopathic hypersomnia and narcolepsy in Q4 2025, forecasting $2.5 billion in peak risk-adjusted sales by 2040. With analysts maintaining a Strong Buy consensus and the company exhibiting robust liquidity and 119% LTM revenue growth, significant upside is projected from its current $16.56 price.

Analysis

Centessa Pharmaceuticals (CNTA) has received a significant vote of confidence from Wall Street, with Oppenheimer resuming coverage with an Outperform rating and a $40 price target, suggesting substantial upside from its current price of $16.56. This bullish thesis, echoed by Truist Securities' reiterated Buy rating with a $30 target, is fundamentally anchored to the potential of its lead asset, ORX750, an orexin-2 receptor agonist. Oppenheimer views ORX750 as a potential best-in-class treatment for narcolepsy and idiopathic hypersomnia, forecasting peak risk-adjusted sales of $2.5 billion by 2040. The company's financial position appears robust for a clinical-stage entity, characterized by a strong current ratio of 10.12, liquid assets that exceed short-term obligations, and moderate debt levels. While LTM revenue growth was reported at 119%, the key value-inflection point for investors is the anticipated Phase 2a CRYSTAL-1 data, expected in Q4 2025. The competitive landscape will gain clarity following presentations on rival OX2R agonists at the World Sleep conference in September 2025, which will be a critical event for assessing ORX750's market positioning. The recent appointment of a new Chief Accounting Officer from Ernst & Young suggests a strengthening of financial governance as the company approaches these pivotal milestones.

Key Decisions for Investors

• Investors should view Centessa as a catalyst-driven investment, with the primary value inflection point hinging on the Phase 2a clinical data for ORX750 expected in the fourth quarter of 2025.
• It is critical to monitor the competitive landscape, paying close attention to data presented on rival orexin agonists at the World Sleep conference in September 2025 to gauge ORX750's differentiation and market potential.
• Given the strong analyst consensus and the company's robust liquidity profile, which mitigates near-term financing risk, accumulating a position could be considered for portfolios with a high tolerance for binary clinical-stage biotech risk.
• The strong balance sheet, with a current ratio of 10.12, provides a significant financial runway, suggesting the company is well-capitalized to reach its key clinical milestones without imminent shareholder dilution.